Aquavit Pharmaceuticals Expands AI Capabilities with Acquisition of Axon Technologies

Aquavit Pharmaceuticals AG announced the successful acquisition and integration of Axon Technologies AG, formerly known as Genève Technologies, marking a strategic leap forward in artificial intelligence (AI) and advanced life-science innovation.

“By bringing Axon Technologies into the Aquavit family, we fuse world-class expertise in pharmaceutical development with state-of-the-art artificial intelligence,” said Sobin Chang, MPH, CEO and Chairman. “This combination positions us to accelerate drug and device developments, optimize global medical logistics and commercialization, and pioneer AI-driven healthcare solutions.”

Aquavit Pharmaceuticals AG also retains the flexibility to acquire complementary businesses and to manage intellectual property and related assets worldwide.

Strengthening AI Leadership

Axon Technologies—formerly incorporated as Genève Technologies—is recognized for its purpose of “developing and commercializing applications and technologies in the field of artificial intelligence.”